© December 2025 | IJIRT | Volume 12 Issue 7 | ISSN: 2349-6002

“Deep Learning–Enhanced MRI Analysis for Early Prediction of Alzheimer’s Disease”

Ajeet Singh[1], Tanushka Singh[2], Prashant Mishra[3], Vishwas Dixit[4], Dr Manju Pandey[5]
[1,2,3,4,5]*Institute of Pharmacy, Shri Ramswaroop Memorial University, Lucknow Deva Road Lucknow Uttar Pradesh.*

Abstract— **Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired reasoning. It is the leading cause of dementia in older adults, marked by the pathological accumulation of amyloid-beta plaques and neurofibrillary tangles. These pathological changes lead to widespread neuronal damage, significantly impacting daily functioning and quality of life. Providing an overview of the current state of AI applications in neuroimaging for early AD prediction and highlighting the promise of AI techniques to improve early AD diagnosis, prognosis, and management are the goals of this literary review. To give a nuanced examination of the topic, this study uses a targeted descriptive review technique that includes analysis of peer-reviewed papers and clinical trials from the body of current literature. The effectiveness of non-invasive biomarkers, biosensors, and new, promising technologies for improving early AD and PD diagnosis is highlighted in this review.**

Index Terms— **Alzheimer’s disease (AD), Machine learning, MRI Analysis, Imaging analysis**

Geographical Abstract:



I. INTRODUCTION

1.1 Brief Overview of Alzheimer’s Disease

Alzheimer's disease is a neurological condition that gradually impairs thinking and memory abilities, leading to the eventual inability to perform even the most basic tasks. Individuals who have Alzheimer's disease also undergo behavioural and personality changes. (7) Alzheimer's disease is thought to affect about 6 million Americans, many of whom are 65 years of age or older. That's more people with Alzheimer's than there are people in a big American metropolis. The lives of many more people are affected by Alzheimer's as friends and relatives of those who have the illness. [10,18, 21, 25, 26] Dementia is the term used to describe the cognitive, memory, reasoning, and behavioural deficits that are hallmarks of Alzheimer's disease. For this reason, Alzheimer's disease is sometimes called "dementia." Age-related changes in the brain include blood vessel damage, inflammation, shrinkage, and cellular energy breakdown, which can damage neurons and impact other brain cells. This paper summarizes the most widely used deep learning approaches for diagnosing [6, 7, 8,33]. This review provides an important reference to the general direction of ongoing research aimed at using brain MRI image analysis to diagnose Alzheimer's disease, even though it does not fully encompass all pertinent papers. (16, 25,55).



Figure. 1. Factor Influencing of Alzheimer's disease



Figure 2: Alzheimer Disease affection area on Brain Part

1.2 Importance of Early Detection and the role of AI in Medical Imaging: -Effective prophylactic measures must be put in place as soon as Alzheimer's disease (AD) is identified. A quick diagnosis is essential to controlling AD's high incidence rate because it is the most common chronic disorder among the elderly, affecting a sizable section of the aging population. [28] Since AD is a major cause of dementia globally, prompt and accurate diagnostic methods are required. Accordingly, there are several possible causes of AD that impact older people's behaviour, memory, and thought processes. Conventional methods, which can require a large amount of manual labour, depend on clinical evaluations and neuroimaging analysis. [31,35,36]. Deep learning (DL), with its ability to automatically extract meaningful features from data, has emerged as a transformative tool in medical imaging, particularly in detecting and classifying AD from modalities such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) scans Classification tasks in AD detection aim to categorize patients into healthy, mild cognitive impairment (MCI), or AD groups. This process helps in early intervention, particularly in MCI cases where the disease might progress to AD. [41,44,46] The most widely utilized neuroimaging modalities are CT, which aids in detecting structural abnormalities, PET, which provides functional insights by capturing metabolic changes, and MRI, which provides structural information that allows for the detection of brain shrinkage (Wu et al. 2019; AlSaeed and Omar 2022).[37,38]. The brain mass of people with Alzheimer's disease is significantly reduced; Fig. 3 shows the brain masses of people with Alzheimer's and those without the condition. Brain shrinkage is minor or non-existent in people with appropriate cognitive abilities. However, people with MCI lose between 1% to 2% of their brain volume each year, which is a lot quicker than normal aging (Huang et al. 2020). [24] The rate of brain volume loss in AD rises even more, hitting 3–5% annually. Particularly impacted areas include the hippocampus, where shrinking rates can reach 10% to 15% per year. [43,47]

II. MODELS FOR DEEP LEARNING

2.1. Neural networks with convolutions: -

Convolution layers, pooling layers, and fully connected layers are the three main parts of the traditional Convolutional Neural Network (CNN), a powerful deep learning architecture. The model can effectively interpret and evaluate images thanks to its structure, which is based on the principles of human visual perception. [34] The input image is efficiently broken up into smaller, easier-to-manage parts at the convolution layer by employing convolution kernels to extract local features like edges, textures, and patterns. [36,37,38] Through abstraction techniques like max-pooling or average pooling, the pooling layer then shrinks the spatial dimensions of the feature maps, producing a compressed representation of the picture features. Last but not least, the fully connected layer compiles the features that have been extracted and classifies the data according to the input. [42,43]



Figure. 3 Formation of classic convolutional neural network and human visual

2.2 Network of Attention

Deep learning models' attention mechanisms are based on the human visual attention mechanism [22]. The human eye selectively focuses on particular elements based on their significance and pertinence, rather than processing a scene in its whole at once. [16,18,41] Humans can interpret visual information efficiently because they gradually learn to focus on areas of interest within comparable scenes.[13] By focusing on pertinent portions of the input data, deep learning models with attention mechanisms mimic this idea. A number of weight parameters, also known as attention distribution coefficients, are used to do this. The model uses these parameters to assess each input region's significance for a given task. [41]



Figure. 4 Demonstrates an example using an MRI image sample (source) containing numerous regions (value).

2.3Autoencoder

The encoder and the decoder are the two main parts of the Autoencoder model. Together, these elements allow the model to recognize high-performance features in an image and recognize unique distribution patterns of different characteristics, which leads to successful classification and diagnosis. [51,52] By compressing the input image during the encoding process, the key features are efficiently chosen from a high-dimensional space. The decoder process then reconstructs the image, using the high-performance features that the encoder collected to restore an image that closely resembles the original, as shown in [55]. These two procedures enable neural networks using Autoencoder models to recognize both unique distribution patterns of different features and high-performance features in an image. For instance, the model is able to identify variations in the patterns of pixel distribution among samples that fall into several groups. This feature makes the Autoencoder a useful tool in the fields of deep learning and image analysis since it enables it to attain a high degree of classification and diagnostic accuracy across a wide range of applications.

2.4 Generative adversarial network

Generative Adversarial Networks (GANs) consist of two primary components: the generator and the discriminator. The generator is responsible for creating simulated data, while the discriminator determines whether the input data is real or generated. These two components interact in an adversarial manner, driving each other to improve their respective performances. [56,57] The generator continuously adjusts its parameters during the creation process to provide data that closely mimics real data. At the same time, the discriminator adjusts its settings to improve its capacity to differentiate between actual and produced information. A dynamic process of reciprocal improvement is the outcome of this antagonistic interaction between the discriminator and the generator. [67,68]. It is possible to find significant differences between data from different categories and detect possible similarities between samples within the same category by continuously optimizing the parameters of each node in the neural network model. In the end, this procedure makes it easier to classify and diagnose the samples. Researchers can produce realistic, high-quality data samples for a variety of uses, such as data augmentation and picture synthesis, by utilizing the special qualities of GANs. [31,34]. These two procedures enable neural networks using Autoencoder models to recognize both unique distribution patterns of different features and high-performance features in an image. For instance, the model is able to identify variations in the patterns of pixel distribution among samples that fall into several groups. This feature makes the Autoencoder a useful tool in the fields of deep learning and image analysis since it enables it to attain a high degree of classification and diagnostic accuracy across a wide range of applications.



Figure 5. AI model target of Alzheimer' s Diagnosis

III. DATA PROCESSING AND MODEL TRAINING

3.1 Class balance

It can be difficult to diagnose Alzheimer's disease at different stages because of potential category imbalances. Specifically, even though the early stage of Alzheimer's disease is the most crucial for an accurate diagnosis, the sample size is typically [51]. It is challenging to identify trustworthy trends in the underrepresented groups due to the unequal sample distribution.[54] A classification model is susceptible to overfitting when it is constructed using such unbalanced datasets, particularly for the categories with little data samples. As a result, the model may operate less accurately and robustly than ideal when faced with recently gathered data. [57,58] Many researchers use data augmentation techniques to enhance the number of samples for categories with fewer cases in order to address this problem. Data augmentation helps to balance the representation of multiple categories and improves the model's generalization across diverse data points by artificially creating extra samples using techniques like image rotation, flipping, or cropping. [61,62] Another strategy to lessen category imbalances is to dilute samples from overrepresented categories, albeit this is used less frequently. By bringing the overrepresented categories closer to the underrepresented ones, this technique includes lowering the number of samples in those categories. Nevertheless, this strategy can result in the loss of important data from the deleted samples.[68]



Figure 6- Process of generative adversarial network.

3.2 Transfer learning

The dependence of artificial intelligence-based techniques on vast amounts of data samples for efficient training is a noteworthy characteristic. [37,38,39] When using brain MRI pictures to diagnose Alzheimer's disease, it can be difficult to get a significant number of high-quality images. Furthermore, combining photos from several devices as input for model training might seriously impair the model's performance, resulting in a lack of training samples and less-than-ideal results. In order to address this issue, several academics have turned to the transfer learning approach. This method, shown in Fig. 5, pre-trains models by utilizing large natural or medical picture datasets. The model acquires a fundamental breadth of knowledge by using such vast and varied datasets for initial training. [41,44,45] This information can then be improved and customized to meet a specific goal, improving the model's performance and getting around limitations brought on by the lack of high-quality, disease-specific MRI data. In the end, this approach results in a better and more effective analytical procedure. [51,56]

3.3Contrastive Learning

One self-supervised learning technique used to identify the general characteristics of samples is contrastive learning. This method eliminates the need for explicit labelling by enabling the model to determine the degree of similarity or dissimilarity (via feature distance calculation) among samples. [28,29] This approach is particularly useful for brain MRI pictures, which naturally exhibit significant similarity because of the inherent anatomical structure. [34,36,38] By focusing on identifying the similarities between similar examples and the differences between dissimilar ones, contrastive learning effectively identifies and examines important areas, a task that would be difficult to complete with unassisted visual inspection. [41] This capacity is particularly helpful when diagnosing Alzheimer's disease because it can be challenging to distinguish between different stages of the illness.[42] Furthermore, in research settings, the application of contrastive learning might assist in avoiding possible mistakes related to manual marking. This is particularly important when defining and differentiating between Alzheimer's disease phases, which may be a difficult and prone to mistakes procedure [44.45]

IV. CURRENT TRENDS IN AI-ENHANCED ALZHEIMER'S DISEASE IMAGING RESEARCH:

4.1. Multimodal imaging analysis: -

A revolutionary method in the study and diagnosis of Alzheimer's disease, multimodal imaging analysis is revolutionizing how we think about this intricate neurodegenerative condition. [74] This novel approach combines information from several imaging modalities, including Computed Tomography (CT), Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI), among others, to provide a comprehensive and detailed representation of the illness. An extensive overview of studies showing the effectiveness of MRI and other image fusion methods in Alzheimer's diagnosis [71] the power of Multimodal Imaging Analysis lies in its ability to harmonize different, yet complementary, imaging data streams. This harmonization unravels the convoluted interaction between structural and metabolic alterations underpinning Alzheimer's disease progression.[68] By integrating diverse structural and functional viewpoints, this multi-pronged approach enables a comprehensive interpretation of the disease's manifestations, propelling forward the pursuit for accurate early diagnosis and effective predictive modeling. [69] In essence, Multimodal Imaging Analysis capitalizes on the synergistic potential of various imaging techniques, casting a brighter light on the multi-faceted attributes of Alzheimer's disease. The adoption of this advanced approach signifies an important milestone in Alzheimer's research, augmenting our capacity to illuminate and tackle the intricate dimensions of this challenging condition.[74]

4.2 Intelligible AI: -

The opacity of artificial intelligence (AI) models' decision-making processes is a significant problem as these models become more complex.[58] The interpretability of AI-driven outputs is frequently obscured by this opacity, which hides the underlying mechanisms.[61] To address this dilemma, a growing amount of research is devoted to the development and refinement of Explainable AI (XAI) models, which is summarized in Table 3. In order to enable understandable insights into the reasoning behind certain diagnoses or predictions made from neuroimaging data, XAI models aim to shed light on the internal logic of AI. XAI models increase transparency and build confidence in AI systems by shedding light on these hitherto mysterious processes. [64,71]

V. DISCUSSION

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into Alzheimer's disease (AD) diagnostics represents a pivotal advancement in modern precision medicine. Unlike conventional diagnostic methods—which often rely on subjective clinical assessment and require invasive or expensive confirmatory tests—AI-based models enable objective, data-driven analysis capable of identifying subtle, early neurodegenerative changes that may not be visible to the human eye. In particular, deep learning approaches, such as Convolutional Neural Networks (CNNs), have demonstrated remarkable efficiency in interpreting MRI scans, identifying cortical atrophy patterns, hippocampal volume loss, and other hallmark changes of AD with high sensitivity and specificity. However, despite promising results, the current study highlights significant limitations in existing AI-based AD models. The foremost challenge is the scarcity of large, diverse, and high-quality datasets. Many models are trained on small sample sizes or non-standardized imaging databases, leading to poor generalizability when applied to real-world clinical settings. Additionally, heterogeneity in MRI acquisition protocols across different scanners and medical centers leads to image variability, ultimately limiting model performance. Another obstacle arises from medical data complexity; traditional machine learning models often struggle to extract meaningful features from 3D neuroimaging data, and input features may fail to align with model architecture, resulting in overfitting or inaccurate predictions. In response to these challenges, the advancement of hardware technologies and the progressive reduction in MRI costs are expected to improve data standardization and accessibility. This would facilitate the expansion of open-access neuroimaging repositories, allowing researchers to build more robust, scalable models. Complementing these advances, the emerging availability of structured electronic medical records (EMR) and genomic sequencing data provides a unique opportunity to develop multimodal AI models. Future deep learning frameworks will likely combine neuroimaging, clinical biomarkers, genetic risk factors (e.g., APOE-ε4), and even blood-based biomarkers such as p-Tau217 and NfL. Such comprehensive, multidimensional models may outperform single-modality algorithms by capturing the multifactorial nature of AD pathology. Moreover, the development of explainable AI (XAI) is crucial for enhancing clinician trust and promoting clinical adoption. Transparent decision-making tools such as Grad-CAM visualization and attention maps can elucidate how models classify AD stages and which brain regions contribute most to predictions. This will ensure AI systems serve as supportive clinical decision aids rather than opaque “black-box” technologies. In conclusion, while current AI models for Alzheimer’s diagnosis face hurdles related to data availability, standardization, and model optimization, emerging technological innovations promise substantial improvements. The integration of multimodal datasets, advancements in imaging technology, and rapid progress in deep learning architectures position AI as a transformative force in AD diagnostics. These developments will not only improve early detection but also facilitate personalized treatment strategies, ultimately revolutionizing Alzheimer’s disease management and patient care.

VI. CONCLUSIONS

The current study addresses a number of important issues noted in earlier studies, such as insufficient input data, model flaws resulting from the switch to medical data, and input data features that are incompatible with the model. The lack of genuine data and open databases has prevented the Alzheimer's disease (AD) model from reaching its full potential. In the future, it is anticipated that improvements in hardware technology would lower the price of MRI equipment and lessen inconsistencies between images captured by various systems. It is therefore expected that the open-access library of brain MRI pictures would grow, enabling additional study and creativity. Furthermore, it is anticipated that the creation of innovative deep learning models will quicken in the upcoming years due to the advancements in gene sequencing technology and organized electronic medical records. These developments will surely have a big impact on improving healthcare data analytics and Alzheimer's disease diagnostic technology, opening the door to more precise and effective diagnosis and treatment of this crippling illness.

REFERENCES

[1] M. Tzioras, R.I. McGeachan, C.S. Durrant, T.L. Spires-Jones, Synaptic degeneration in Alzheimer disease, Nat. Rev. Neurol. 19 (1) (2023) 19–38.

[2] M. Citron, Alzheimer’s disease: treatments in discovery and development, Nat. Neurosci. 5 (11) (2002) 1055–1057.

[3] M. Malpetti, R. La Joie, Imaging Alzheimer’s pathology stage by stage, Nature Aging 2 (6) (2022) 465–467.

[4] K. Iqbal, M. Flory, H. Soininen, A. Alonso, C. Gong, Clinical Symptoms and Symptom Signatures of Alzheimer’s Disease Subgroups, J. Alzheimers Dis. 37 (3) (2013) 475–481.

[5] R.L. Buckner, F.M. Krienen, B.T.T. Yeo, Opportunities and limitations of intrinsic functional connectivity MRI, Nat. Neurosci. 16 (7) (2013) 832–837.

[6] Y. Zhang, Z. Dong, S. Wang, P. Phillips, G. Ji, Prediction of Alzheimer's disease and mild cognitive impairment based on structural volumetric MR images by 3D discrete wavelet transform and artificial neural network, Alzheimers Dement. 11 (2015) P78–P79.

[7] T. Martín-Noguerol, O.L. Casado-Verdugo, L.S. Beltran, ´ G. Aguilar, A. Luna, Role of advanced MRI techniques for sacroiliitis assessment and quantification, Eur. J. Radiol. 163 (2023), 110793.

[8] S.B. Eickhoff, B.T.T. Yeo, S. Genon, Imaging-based parcellations of the human brain, Nat. Rev. Neurosci. 19 (11) (2018) 672–686.

[9] N. Weiskopf, L.J. Edwards, G. Helms, S. Mohammadi, E. Kirilina, Quantitative magnetic resonance imaging of brain anatomy and in vivo histology, Nat. Rev. Phys. 3 (8) (2021) 570–588.

[10] R. Ylikoski, O. Salonen, R. M¨ antyl¨ a, A. Ylikoski, P. Keskivaara, M. Leskela, ¨ T. Erkinjuntti, Hippocampal and temporal lobe atrophy and age-related decline in memory, Acta Neurol. Scand. 101 (4) (2000) 273–278.

[11] M. Smits, MRI biomarkers in neuro-oncology, Nat. Rev. Neurol. 17 (8) (2021) 486–500.

[12] Y. Ding, J.H. Sohn, M.G. Kawczynski, H. Trivedi, R. Harnish, N.W. Jenkins, D. Lituiev, T.P. Copeland, M.S. Aboian, C. Mari Aparici, S.C. Behr, R.R. Flavell, S.- Y. Huang, K.A. Zalocusky, L. Nardo, Y. Seo, R.A. Hawkins, M. Hernandez Pampaloni, D. Hadley, B.L. Franc, A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain, Radiology 290 (2) (2019) 456–464.

[13] K. Etminani, A. Soliman, A. Davidsson, J.R. Chang, B. Martínez-Sanchis, S. Byttner, V. Camacho, M. Bauckneht, R. Stegeran, M. Ressner, A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET, Eur. J. Nucl. Med. Mol. Imaging (2022) 1–22.

[14] M. Raju, V.P. Gopi, V.S. Anitha, K.A. Wahid, Multi-class diagnosis of Alzheimer's disease using cascaded three dimensional-convolutional neural network, Phys. Eng. Sci. Med. 43 (4) (2020) 1219–1228.

[15] C. Salvatore, A. Cerasa, I. Castiglioni, F. Gallivanone, A. Augimeri, M. Lopez, G. Arabia, M. Morelli, M. Gilardi, A. Quattrone, Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy, J. Neurosci. Methods 222 (2014) 230–237.

[16] S. Reddy, J. Fox, M.P. Purohit, Artificial intelligence-enabled healthcare delivery, J. R. Soc. Med. 112 (1) (2019) 22–28.

[17] S. Soffer, A. Ben-Cohen, O. Shimon, M.M. Amitai, H. Greenspan, E. Klang, Convolutional neural networks for radiologic images: a radiologist's guide, Radiology 290 (3) (2019) 590–606.

[18] J. Teuwen, N. Moriakov, in: Handbook of Medical Image Computing and Computer Assisted Intervention, Elsevier, 2020, pp. 481–501.

[19] Z. Liu, H. Mao, C. Wu, C. Feichtenhofer, T. Darrell, S. Xie, A ConvNet for the 2020s, 2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) (2022) 11966-11976. Table 3 Summary of Advancements in Explainable AI for Enhancing Alzheimer's Disease Diagnosis.

[20] S. Sabour, N. Frosst, G.E. Hinton, Dynamic Routing Between Capsules, ArXiv abs/ 1710.09829 (2017).

[21] Y. Xu, M. Vaziri-Pashkam, Limits to visual representational correspondence between convolutional neural networks and the human brain, Nat. Commun. 12 (2021).

[22] A.M. Obeso, J. Benois-Pineau, M.S.G. V´ azquez, A.A.R. ´ Acosta, Visual vs internal attention mechanisms in deep neural networks for Image classification and object detection, Pattern Recogn. 123 (2022), 108411.

[23] L. Itti, C. Koch, Computational modelling of visual attention, Nat. Rev. Neurosci. 2 (3) (2001) 194–203.

[24] M.-H. Guo, T.-X. Xu, J.-J. Liu, Z.-N. Liu, P.-T. Jiang, T.-J. Mu, S.-H. Zhang, R. R. Martin, M.-M. Cheng, S.-M. Hu, Attention mechanisms in computer vision: A survey, Comput. Visual Media 8 (3) (2022) 331–368.

[25] Vaswani, N. Shazeer, N. Parmar, J. Uszkoreit, L. Jones, A.N. Gomez, Ł. Kaiser, I. Polosukhin, Attention is all you need, Adv. Neural Inf. Proces. Syst. 30 (2017).
[26] Z. Dai, Z. Yang, Y. Yang, J. Carbonell, Q.V. Le, R. Salakhutdinov, Transformer-xl: Attentive language models beyond a fixed-length context, arXiv preprint arXiv: 1901.02860 (2019).
[27] S. Sukhbaatar, J. Weston, R. Fergus, End-to-end memory networks, Adv. Neural Inf. Proces. Syst. 28 (2015).
[28] S.M. Anwar, M. Majid, A. Qayyum, M. Awais, M. Alnowami, M.K. Khan, Medical image analysis using convolutional neural networks: a review, J. Med. Syst. 42 (2018) 1–13.
[29] D. Bank, N. Koenigstein, R. Giryes, Autoencoders, ArXiv abs/2003.05991 (2020).
[30] E. Yagis, A.G.S. De Herrera, L. Citi, Convolutional Autoencoder based Deep Learning Approach for Alzheimer's Disease Diagnosis using Brain MRI, 2021 IEEE 34th International Symposium on Computer-Based Medical Systems (CBMS), IEEE, 2021, pp. 486-491.
[31] P. Isola, J.-Y. Zhu, T. Zhou, A.A. Efros, Image-to-image translation with conditional adversarial networks, in: Proceedings of the IEEE conference on computer vision and pattern recognition, 2017, pp. 1125–1134.
[32] X. Yi, E. Walia, P. Babyn, Generative Adversarial Network in Medical Imaging: A Review, Med. Image Anal. 58 (2019) 101552.
[33] G.E. Hinton, R.R. Salakhutdinov, Reducing the dimensionality of data with neural networks, Science 313 (5786) (2006) 504–507.
[34] M. Faturrahman, I. Wasito, N. Hanifah, R. Mufidah, Structural MRI classification for Alzheimer's disease detection using deep belief network, in: 2017 11th International Conference on Information & Communication Technology and System (ICTS), 2017, pp. 37–42.
[35] N. Zeng, H. Li, Y. Peng, A new deep belief network-based multi-task learning for diagnosis of Alzheimer's disease, Neural Comput. & Applic. (2021) 1–12.
[36] J.M. Johnson, T.M. Khoshgoftaar, Survey on deep learning with class imbalance, J. Big Data 6 (1) (2019) 1–54.
[37] M. Mostapha, M. Styner, Role of deep learning in infant brain MRI analysis, Magn. Reson. Imaging 64 (2019) 171–189.
[38] Y. Chen, M. Dang, Z. Zhang, Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and –specific lesion patterns, Mol. Neurodegener. 16 (2021).
[39] L. Kucikova, J. Goerdten, M.-E. Dounavi, E. Mak, L. Su, A.D. Waldman, S. Danso, G. Muniz-Terrera, C.W. Ritchie, Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer's disease, Neurosci. Biobehav. Rev. 129 (2021) 142–153.
[40] A. Ebrahimi-Ghahnavieh, S. Luo, R. Chiong, Transfer Learning for Alzheimer's Disease Detection on MRI Images, in: 2019 IEEE International Conference on Industry 4.0, Artificial Intelligence, and Communications Technology (IAICT), 2019, pp. 133–138.
[41] F. Zhuang, Z. Qi, K. Duan, D. Xi, Y. Zhu, H. Zhu, H. Xiong, Q. He, A Comprehensive Survey on Transfer Learning, Proc. IEEE 109 (1) (2021) 43–76.
[42] [S. Albelwi, Survey on Self-Supervised Learning: Auxiliary Pretext Tasks and Contrastive Learning Methods in Imaging, Entropy 24 (4) (2022) 551.
[43] X. Li, Z. Sun, J.-H. Xue, Z. Ma, A concise review of recent few-shot meta-learning methods, Neurocomputing 456 (2021) 463–468.
[44] X. Wu, L. Xiao, Y. Sun, J. Zhang, T. Ma, L. He, A survey of human-in-the-loop for machine learning, Futur. Gener. Comput. Syst. 135 (2022) 364–381.
[45] A.J. Langdon, M.M. Botvinick, H. Nakahara, K. Tanaka, M. Matsumoto, R. Kanai, Meta-learning, social cognition and consciousness in brains and machines, Neural Networks: Off. J. Int. Neural Network Soc. 145 (2021) 80–89.
[46] T. Li, A.K. Sahu, A.S. Talwalkar, V. Smith, Federated Learning: Challenges, Methods, and Future Directions, IEEE Signal Process Mag. 37 (2019) 50–60.

[47] [47] R.S. Antunes, C. Andr´e da Costa, A. Küderle, I.A. Yari, B. Eskofier, Federated Learning for Healthcare: Systematic Review and Architecture Proposal, ACM Trans. Intell. Syst. Technol. (TIST) 13 (2022) 1–23.

[48] T.S. Brisimi, R. Chen, T. Mela, A. Olshevsky, I.C. Paschalidis, W. Shi, Federated learning of predictive models from federated electronic health records, Int. J. Med. Inf. 112 (2018

[49] H. Li, C. Li, J. Wang, A. Yang, Z. Ma, Z. Zhang, D. Hua, Review on security of federated learning and its application in healthcare, Futur. Gener. Comput. Syst. 144 (2023) 271–290.

[50] S.J. Colloby, R.A. Cromarty, L.R. Peraza, K. Johnsen, G. Johannesson, ´ L. Bonanni, M. Onofrj, R. Barber, J.T. O'Brien, J.P. Taylor, Multimodal EEG-MRI in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies, J. Psychiatr. Res. 78 (2016) 48–55.

[51] Y. Wang, Y. Yang, X. Guo, C. Ye, N. Gao, Y. Fang, H.T. Ma, A Novel Multimodal MRI Analysis for Alzheimer's Disease Based on Convolutional Neural Network, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2018 (2018) 754-757.

[52] R. Polikar, C. Tilley, B. Hillis, C.M. Clark, Multimodal EEG, MRI and PET data fusion for Alzheimer's disease diagnosis, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2010 (2010) 6058-61.

[53] M. Waser, T. Benke, P. Dal-Bianco, H. Garn, J.A. Mosbacher, G. Ransmayr, R. Schmidt, S. Seiler, H.B.D. Sorensen, P.J. Jennum, Neuroimaging markers of global cognition in early Alzheimer's disease: A magnetic resonance imagingelectroencephalography study, Brain Behavior 9 (1) (2019) e01197. [

[54] R. Ferri, C. Babiloni, V. Karami, A.I. Triggiani, F. Carducci, G. Noce, R. Lizio, M. T. Pascarelli, A. Soricelli, F. Amenta, A. Bozzao, A. Romano, F. Giubilei, C. Del Percio, F. Stocchi, G.B. Frisoni, F. Nobili, L. Patan`e, P. Arena, Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements, Clin. Neurophysiol. 132 (1) (2021) 232–245.

[55] T. Patel, R. Polikar, C. Davatzikos, C.M. Clark, EEG and MRI data fusion for early diagnosis of Alzheimer's disease, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2008 (2008) 1757-60.

[56] J. Venugopalan, L. Tong, H.R. Hassanzadeh, M.D. Wang, Multimodal deep learning models for early detection of Alzheimer's disease stage, Sci Rep 11 (1) (2021) 3254.

[57] X. Meng, Q. Wei, L.i. Meng, J. Liu, Y. Wu, W. Liu, Feature Fusion and Detection in Alzheimer's Disease Using a Novel Genetic Multi-Kernel SVM Based on MRI Imaging and Gene Data, Genes 13 (5) (2022) 837.

[58] Z. Hu, X*. Wang, L.i. Meng, W. Liu, F. Wu, X. Meng, Detection of Association Features Based on Gene Eigenvalues and MRI Imaging Using Genetic Weighted Random Forest, Genes 13 (12) (2022) 2344.

[59] X.A. Bi, L. Li, R. Xu, Z. Xing, Pathogenic Factors Identification of Brain Imaging and Gene in Late Mild Cognitive Impairment, Interdiscipl. Sci. Comput. Life Sci. 13 (3) (2021) 511–520.

[60] K. Ning, B. Chen, F. Sun, Z. Hobel, L. Zhao, W. Matloff, A.W. Toga, Classifying Alzheimer's disease with brain imaging and genetic data using a neural network framework, Neurobiol. Aging 68 (2018) 151–158.

[61] S. Qiu, P.S. Joshi, M.I. Miller, C. Xue, X. Zhou, C. Karjadi, G.H. Chang, A.S. Joshi, B. Dwyer, S. Zhu, M. Kaku, Y. Zhou, Y.J. Alderazi, A. Swaminathan, S. Kedar, M.- H. Saint-Hilaire, S.H. Auerbach, J. Yuan, E.A. Sartor, R. Au, V.B. Kolachalama, Development and validation of an interpretable deep learning framework for Alzheimer's disease classification, Brain 143 (6) (2020) 1920–1933.

[62] [62] B.M. Cobbinah, C. Sorg, Q. Yang, A. Ternblom, C. Zheng, W. Han, L. Che, J. Shao, Reducing variations in multi-center

Alzheimer's disease classification with convolutional adversarial autoencoder, Med. Image Anal. 82 (2022), 102585.

[63] M. Bohle, ¨ F. Eitel, M. Weygandt, K. Ritter, Layer-Wise Relevance Propagation for Explaining Deep Neural Network Decisions in MRI-Based Alzheimer's Disease Classification, Front. Aging Neurosci. 11 (2019) 194.

[64] O. Kwanseok, D.-W. Heo, A.W. Mulyadi, W. Jung, E. Kang, H.-I. Suk, Quantifying Explainability of Counterfactual-Guided MRI Feature for Alzheimer's Disease Prediction, 2022.

[65] A.W. Mulyadi, W. Jung, K. Oh, J.S. Yoon, K.H. Lee, H.I. Suk, Estimating explainable Alzheimer's disease likelihood map via clinically-guided prototype learning, Neuroimage 273 (2023), 120073.

[66] M. Jiwa, S. Millett, X. Meng, V.M. Hewitt, Impact of the presence of medical equipment in images on viewers' perceptions of the trustworthiness of an individual on-screen, J. Med. Internet Res. 14 (4) (2012) e1986.

[67] C.R. Jack Jr, M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, D. Harvey, B. Borowski, P.J. Britson, J.L. Whitwell, C. Ward, The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods, Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for, Magn. Reson. Med. 27 (4) (2008) 685–691.

[68] T. Condie, P. Mineiro, N. Polyzotis, M. Weimer, Machine learning for big data, Proceedings of the 2013 ACM SIGMOD International Conference on Management of Data, 2013, pp. 939-942.

[69] Bergeron D, Sellami L, Poulin S, Verret L, Bouchard RW, Laforce R Jr. The behavioral/dysexecutive variant of Alzheimer's disease: a case series with clinical, neuropsychological, and FDG-PET characterization. Dement Geriatr Cogn Disord. 2020; 49:518–25.

[70] Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12:292–323.

[71] Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimers Dement (N Y). 2023;9:e12377.

[72] Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989–97.

[73] Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain. 2020;143:3234–41.

[74] Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, et al. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. J Neurol. 2019;266:2535–45.

[75] Balasa M, Gelpi E, Antonell A, Rey MJ, Sánchez-Valle R, Molinuevo JL, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology. 2011;76:1720–5